Bioengineered hydrogels enhance ex vivo preservation of patient-derived tumor explants for drug evaluation
Christabella Adine,Kanishka Fernando,Nicholas Ching Wei Ho,Hong Sheng Quah,Samantha Shu Wen Ho,Kenny Zhuoran Wu,Karen Wei Weng Teng,Camille Arcinas,Ling Li,Kelly Ha,Joey Wei Ling Chew,Chenhui Wang,Nathaniel Sheng Hua Too,Joe Poh Sheng Yeong,Daniel Shao Weng Tan,Iain Bee Huat Tan,Rahul Nagadia,Claramae Shulyn Chia,Dominique Macalinao,Hariraman Bhuvaneswari,N Gopalakrishna Iyer,Eliza Li Shan Fong
DOI: https://doi.org/10.1016/j.biomaterials.2023.122460
IF: 14
2024-01-03
Biomaterials
Abstract:Ex vivo patient-derived tumor slices (PDTS) are currently limited by short-term viability in culture. Here, we show how bioengineered hydrogels enable the identification of key matrix parameters that significantly enhance PDTS viability compared to conventional culture systems. As demonstrated using single-cell RNA sequencing and high-dimensional flow cytometry, hydrogel-embedded PDTS tightly preserved cancer, cancer-associated fibroblast, and various immune cell populations and subpopulations in the corresponding original tumor. Cell-cell communication networks within the tumor microenvironment, including immune checkpoint ligand-receptor interactions, were also maintained. Remarkably, our results from a co-clinical trial suggest hydrogel-embedded PDTS may predict sensitivity to immune checkpoint inhibitors (ICIs) in head and neck cancer patients. Further, we show how these longer term-cultured tumor explants uniquely enable the sampling and detection of temporal evolution in molecular readouts when treated with ICIs. By preserving the compositional heterogeneity and complexity of patient tumors, hydrogel-embedded PDTS provide a valuable tool to facilitate experiments targeting the tumor microenvironment.
engineering, biomedical,materials science, biomaterials